Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Protocol for a prospective collaborative systematic review and meta-analysis of individual patient data from randomized controlled trials of vasoactive drugs in acute stroke: The Blood pressure in Acute Stroke Collaboration, stage-3.

Sandset EC, Sanossian N, Woodhouse LJ, Anderson C, Berge E, Lees KR, Potter JF, Robinson TG, Sprigg N, Wardlaw JM, Bath PM; Blood pressure in Acute Stroke Collaboration Investigators.

Int J Stroke. 2018 Jan 1:1747493018772733. doi: 10.1177/1747493018772733. [Epub ahead of print]

PMID:
29720045
2.

Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data.

Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC Jr., Yusuf S, Zanchetti A, Glasziou P, Jackson R, Woodward M, Rodgers A, Neal BC, Berge E, Teo K, Davis BR, Chalmers J, Pepine C, Rahimi K, Sundström J; Blood Pressure Lowering Treatment Trialists’ Collaboration.

PLoS Med. 2018 Mar 20;15(3):e1002538. doi: 10.1371/journal.pmed.1002538. eCollection 2018 Mar.

3.

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.

Bruins Slot KM, Berge E.

Cochrane Database Syst Rev. 2018 Mar 6;3:CD008980. doi: 10.1002/14651858.CD008980.pub3. Review.

PMID:
29509959
4.

Effect of strenuous exercise on mediators of inflammation in patients with coronary artery disease.

Cwikiel J, Seljeflot I, Berge E, Njerve IU, Ulsaker H, Arnesen H, Flaa A.

Cytokine. 2018 May;105:17-22. doi: 10.1016/j.cyto.2018.02.006. Epub 2018 Feb 9.

PMID:
29433015
5.

Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage.

Seiffge DJ, Kägi G, Michel P, Fischer U, Béjot Y, Wegener S, Zedde M, Turc G, Cordonnier C, Sandor PS, Rodier G, Zini A, Cappellari M, Schädelin S, Polymeris AA, Werring D, Thilemann S, Maestrini I, Berge E, Traenka C, Vehoff J, De Marchis GM, Kapauer M, Peters N, Sirimarco G, Bonati LH, Arnold M, Lyrer PA, De Maistre E, Luft A, Tsakiris DA, Engelter ST; Novel Oral Anticoagulants in Stroke Patients study group.

Ann Neurol. 2018 Mar;83(3):451-459. doi: 10.1002/ana.25165. Epub 2018 Mar 3.

PMID:
29394504
6.

Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.

Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, Mancia G, Parati G, Weber MA, Berge E.

Eur Heart J. 2018 Jan 20. doi: 10.1093/eurheartj/ehx760. [Epub ahead of print]

PMID:
29365085
7.

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.

Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S.

Ann Intern Med. 2018 Mar 6;168(5):326-334. doi: 10.7326/M17-0101. Epub 2018 Jan 16.

PMID:
29335712
8.

Relationship between race and outcome in Asian, Black, and Caucasian patients with spontaneous intracerebral hemorrhage: Data from the Virtual International Stroke Trials Archive and Efficacy of Nitric Oxide in Stroke trial.

Krishnan K, Beishon L, Berge E, Christensen H, Dineen RA, Ozturk S, Sprigg N, Wardlaw JM, Bath PM; VISTA-ICH collaboration and ENOS Investigators.

Int J Stroke. 2018 Jun;13(4):362-373. doi: 10.1177/1747493017744463. Epub 2017 Nov 22.

PMID:
29165060
9.

How to do a systematic review.

Pollock A, Berge E.

Int J Stroke. 2018 Feb;13(2):138-156. doi: 10.1177/1747493017743796. Epub 2017 Nov 17.

PMID:
29148960
10.

Enlarged perivascular spaces are associated with health-related quality of life in patients with acute ischemic stroke.

Liang Y, Deng M, Chen YK, Mok V, Wang DF, Ungvari GS, Chu CW, Berge E, Tang WK.

CNS Neurosci Ther. 2017 Dec;23(12):973-979. doi: 10.1111/cns.12766. Epub 2017 Oct 20.

PMID:
29052954
11.

Long-term predictors of stroke in healthy middle-aged men.

Prestgaard E, Hodnesdal C, Engeseth K, Erikssen J, Bodegård J, Liestøl K, Gjesdal K, Kjeldsen SE, Grundvold I, Berge E.

Int J Stroke. 2018 Apr;13(3):292-300. doi: 10.1177/1747493017730760. Epub 2017 Sep 20.

PMID:
28929941
12.

Blood pressure variability and leukoaraiosis in acute ischemic stroke.

Dickie DA, Aribisala B, Mair G, Berge E, Lindley RI, Sandercock P, von Kummer R, von Heijne A, Peeters A, Cala L, Farrall A, Morris Z, Bradey N, Potter G, Adami A, Wardlaw JM.

Int J Stroke. 2017 Jan 1:1747493017729267. doi: 10.1177/1747493017729267. [Epub ahead of print]

PMID:
28872448
13.

Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial.

Woodhouse LJ, Scutt P, Hamdy S, Smithard DG, Cohen DL, Roffe C, Bereczki D, Berge E, Bladin CF, Caso V, Christensen HK, Collins R, Czlonkowska A, de Silva A, Etribi A, Laska AC, Ntaios G, Ozturk S, Phillips SJ, Prasad K, Szatmari S, Sprigg N, Bath PM.

Transl Stroke Res. 2018 Apr;9(2):120-129. doi: 10.1007/s12975-017-0548-0. Epub 2017 Aug 2.

14.

Infections Up to 76 Days After Stroke Increase Disability and Death.

Learoyd AE, Woodhouse L, Shaw L, Sprigg N, Bereczki D, Berge E, Caso V, Christensen H, Collins R, Czlonkowska A, El Etribi A, Farr TD, Gommans J, Laska AC, Ntaios G, Ozturk S, Pocock SJ, Prasad K, Wardlaw JM, Fone KC, Bath PM, Trueman RC; ENOS Trial investigators.

Transl Stroke Res. 2017 Dec;8(6):541-548. doi: 10.1007/s12975-017-0553-3. Epub 2017 Jul 27.

15.

Antithrombotic treatment after stroke due to intracerebral haemorrhage.

Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R.

Cochrane Database Syst Rev. 2017 May 25;5:CD012144. doi: 10.1002/14651858.CD012144.pub2. Review.

PMID:
28540976
16.

Should elevated blood pressure be lowered in the acute phase of ischaemic stroke?

Berge E.

J Hypertens. 2017 Jun;35(6):1166-1167. doi: 10.1097/HJH.0000000000001338. No abstract available.

PMID:
28441257
17.

Increasing value and reducing waste in stroke research.

Berge E, Al-Shahi Salman R, van der Worp HB, Stapf C, Sandercock P, Sprigg N, Macleod MR, Kelly PJ, Nederkoorn PJ, Ford GA; European Stroke Organisation Trials Network Committee.

Lancet Neurol. 2017 May;16(5):399-408. doi: 10.1016/S1474-4422(17)30078-9. Review.

PMID:
28414653
18.

Continuing or Temporarily Stopping Prestroke Antihypertensive Medication in Acute Stroke: An Individual Patient Data Meta-Analysis.

Woodhouse LJ, Manning L, Potter JF, Berge E, Sprigg N, Wardlaw J, Lees KR, Bath PM, Robinson TG; Blood Pressure in Acute Stroke Collaboration.

Hypertension. 2017 May;69(5):933-941. doi: 10.1161/HYPERTENSIONAHA.116.07982. Epub 2017 Mar 6.

19.

Thrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data?

Barer D, Berge E.

Drugs Aging. 2017 Feb;34(2):79-88. doi: 10.1007/s40266-016-0432-8. Review.

PMID:
28120326
20.

Pro-coagulant activity during exercise testing in patients with coronary artery disease.

Cwikiel J, Seljeflot I, Berge E, Arnesen H, Wachtell K, Ulsaker H, Flaa A.

Thromb J. 2017 Jan 19;15:3. doi: 10.1186/s12959-016-0127-8. eCollection 2017.

21.

Predictors of Poor Prognosis in Recurrent Hepatitis C After Liver Transplantation.

Berge E, Otón E, Reina Z, Díaz L, Márquez A, Cejas L, Acosta S, Pérez F.

Transplant Proc. 2016 Nov;48(9):2997-2999. doi: 10.1016/j.transproceed.2016.07.043.

PMID:
27932129
22.

Mortality after thrombolysis - Authors' reply.

Berge E, Cohen G, Wardlaw JM, Sandercock PAG, Whiteley WN.

Lancet Neurol. 2016 Dec;15(13):1305. doi: 10.1016/S1474-4422(16)30280-0. No abstract available.

PMID:
27839642
23.

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Heart. 2017 Feb 15;103(4):307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.

24.

Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.

Berge E, Cohen G, Roaldsen MB, Lundström E, Isaksson E, Rudberg AS, Slot KB, Forbes J, Smith J, Drever J, Wardlaw JM, Lindley RI, Sandercock PA, Whiteley WN; IST-3 Collaborative Group.

Lancet Neurol. 2016 Sep;15(10):1028-34. doi: 10.1016/S1474-4422(16)30139-9. Epub 2016 Jul 20.

PMID:
27450474
25.

Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the Scandinavian Candesartan Acute Stroke Trial (SCAST).

Jusufovic M, Sandset EC, Bath PM, Berge E; Scandinavian Candesartan Acute Stroke Trial (SCAST) Study Group.

J Hypertens. 2016 Aug;34(8):1594-8. doi: 10.1097/HJH.0000000000000980.

PMID:
27228435
26.

Effect of Treatment Delay, Stroke Type, and Thrombolysis on the Effect of Glyceryl Trinitrate, a Nitric Oxide Donor, on Outcome after Acute Stroke: A Systematic Review and Meta-Analysis of Individual Patient from Randomised Trials.

Bath PM, Woodhouse L, Krishnan K, Anderson C, Berge E, Ford GA, Robinson TG, Saver JL, Sprigg N, Wardlaw JM, In Acute Stroke Collaboration Basc BP.

Stroke Res Treat. 2016;2016:9706720. doi: 10.1155/2016/9706720. Epub 2016 Apr 17.

27.

Methods to improve patient recruitment and retention in stroke trials.

Berge E, Stapf C, Al-Shahi Salman R, Ford GA, Sandercock P, van der Worp HB, Petersson J, Dippel DW, Krieger DW, Lees KR; ESO Trials Network Committee.

Int J Stroke. 2016 Aug;11(6):663-76. doi: 10.1177/1747493016641963. Epub 2016 Apr 26. Review.

PMID:
27118766
28.

Blood Pressure Management in Acute Stroke.

Jusufovic M, Mishra NK, Lansberg MG, Bath PM, Berge E, Sandset EC.

Curr Hypertens Rev. 2016;12(2):121-6. Review.

PMID:
26931471
29.

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba-Badiale M, Silani V, Bilo G, Corrao G, Zambon A, Scotti L, Zhang X, Guan TR, Zhang Y, Zhang X, Berge E, Redon J, Narkiewicz K, Dominiczak A, Nilsson P, Viigimaa M, Laurent S, Agabiti-Rosei E, Wu Z, Zhu D, Rodicio JL, Ruilope LM, Martell-Claros N, Pinto F, Schmieder RE, Burnier M, Banach M, Cifkova R, Farsang C, Konradi A, Lazareva I, Sirenko Y, Dorobantu M, Postadzhiyan A, Accetto R, Jelakovic B, Lovic D, Manolis AJ, Stylianou P, Dicker D, Wei G, Xu C, Xie H, Coca A, O'Brien J, Ford G; ESH-CHL-SHOT trial investigators.

J Hypertens. 2016 Mar;34(3):393-6. doi: 10.1097/HJH.0000000000000853. No abstract available.

PMID:
26780185
30.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.

McCoach CE, Berge EM, Lu X, Barón AE, Camidge DR.

J Thorac Oncol. 2016 Mar;11(3):407-13. doi: 10.1016/j.jtho.2015.10.024. Epub 2015 Dec 25.

31.

Glyceryl Trinitrate for Acute Intracerebral Hemorrhage: Results From the Efficacy of Nitric Oxide in Stroke (ENOS) Trial, a Subgroup Analysis.

Krishnan K, Scutt P, Woodhouse L, Adami A, Becker JL, Berge E, Cala LA, Casado AM, Caso V, Chen C, Christensen H, Collins R, Czlonkowska A, Dineen RA, Gommans J, Koumellis P, Lees KR, Ntaios G, Ozturk S, Phillips SJ, Pocock SJ, de Silva A, Sprigg N, Szatmari S, Wardlaw JM, Bath PM.

Stroke. 2016 Jan;47(1):44-52. doi: 10.1161/STROKEAHA.115.010368. Epub 2015 Dec 8.

32.

Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome.

Tomi AL, Belkhir R, Nocturne G, Desmoulins F, Berge E, Pavy S, Miceli-Richard C, Mariette X, Seror R.

Arthritis Rheumatol. 2016 May;68(5):1245-50. doi: 10.1002/art.39534.

33.

No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.

Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauer B, Hua TA, Zappe D, Zanchetti A, Weber MA, Julius S.

Blood Press. 2016;25(2):83-92. doi: 10.3109/08037051.2015.1106750. Epub 2015 Oct 29.

PMID:
26511535
34.

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?

Payet J, Belkhir R, Gottenberg JE, Bergé E, Desmoulins F, Meyer O, Mariette X, Seror R.

RMD Open. 2015 Apr 30;1(1):e000066. doi: 10.1136/rmdopen-2015-000066. eCollection 2015.

35.

Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke.

Berge E, Cohen G, Lindley RI, Sandercock P, Wardlaw JM, Sandset EC, Whiteley W.

Stroke. 2015 Dec;46(12):3362-9. doi: 10.1161/STROKEAHA.115.010319. Epub 2015 Oct 20.

36.

Effect of Hyperacute Administration (Within 6 Hours) of Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, on Outcome After Stroke: Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial.

Woodhouse L, Scutt P, Krishnan K, Berge E, Gommans J, Ntaios G, Wardlaw J, Sprigg N, Bath PM; ENOS Investigators.

Stroke. 2015 Nov;46(11):3194-201. doi: 10.1161/STROKEAHA.115.009647. Epub 2015 Oct 13.

37.

Blood pressure and early neurological deterioration in acute ischemic stroke.

Kjeldsen SE, Berge E.

J Hypertens. 2015 Oct;33(10):2020-1. doi: 10.1097/HJH.0000000000000689. No abstract available.

PMID:
26431189
38.

Prognostic value of 24-h ABPM in acute ischemic stroke for short-, medium-, and long-term outcome: a systematic review and meta-analysis.

Kakaletsis N, Ntaios G, Milionis H, Haidich AB, Makaritsis K, Savopoulos C, Berge E, Hatzitolios AI.

Int J Stroke. 2015 Oct;10(7):1000-7. doi: 10.1111/ijs.12609. Epub 2015 Aug 18. Review.

PMID:
26283262
39.

Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.

Seiffge DJ, Hooff RJ, Nolte CH, Béjot Y, Turc G, Ikenberg B, Berge E, Persike M, Dequatre-Ponchelle N, Strbian D, Pfeilschifter W, Zini A, Tveiten A, Næss H, Michel P, Sztajzel R, Luft A, Gensicke H, Traenka C, Hert L, Scheitz JF, De Marchis GM, Bonati LH, Peters N, Charidimou A, Werring DJ, Palm F, Reinhard M, Niesen WD, Nagao T, Pezzini A, Caso V, Nederkoorn PJ, Kägi G, von Hessling A, Padjen V, Cordonnier C, Erdur H, Lyrer PA, Brouns R, Steiner T, Tatlisumak T, Engelter ST; NOACISP Study Group*.

Circulation. 2015 Sep 29;132(13):1261-9. doi: 10.1161/CIRCULATIONAHA.115.015484. Epub 2015 Jul 31.

40.

3D.01: VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY INCREASES RISK OF STROKE OR CARDIAC EVENTS IN PATIENTS GIVEN VALSARTAN OR AMLODIPINE IN THE VALUE TRIAL.

Mehlum M, Liestøl K, Julius S, Kjeldsen SE, Hua TA, Rothwell PM, Mancia G, Parati G, Weber MA, Berge E.

J Hypertens. 2015 Jun;33 Suppl 1:e40. doi: 10.1097/01.hjh.0000467454.55397.ea.

PMID:
26102813
41.

Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months.

Hornslien AG, Sandset EC, Wyller TB, Berge E; Scandinavian Candesartan Acute Stroke Trial (SCAST) Study Group.

J Hypertens. 2015 Jul;33(7):1487-91. doi: 10.1097/HJH.0000000000000581.

PMID:
26039534
42.

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.

43.

Increased life expectancy for physically active Norwegians.

Berge E.

Br J Sports Med. 2015 Jun;49(11):702. doi: 10.1136/bjsports-2015-094867. No abstract available.

PMID:
25979921
44.

Blood pressure-lowering treatment in acute intracerebral haemorrhage.

Berge E.

J Hypertens. 2015 May;33(5):931-2. doi: 10.1097/HJH.0000000000000537. No abstract available.

PMID:
25909696
45.

Cochrane reviewers' response to Alper and colleagues' analysis of thrombolysis in acute ischaemic stroke.

Wardlaw J, Berge E.

BMJ. 2015 Apr 7;350:h1790. doi: 10.1136/bmj.h1790. No abstract available.

PMID:
25850827
46.

Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).

Hornslien AG, Sandset EC, Igland J, Terént A, Boysen G, Bath PM, Murray GD, Berge E.

Int J Stroke. 2015 Aug;10(6):830-5. doi: 10.1111/ijs.12477. Epub 2015 Mar 22.

PMID:
25808741
47.

Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke.

Sandset EC, Jusufovic M, Sandset PM, Bath PM, Berge E; SCAST Study Group.

Stroke. 2015 Mar;46(3):877-9. doi: 10.1161/STROKEAHA.114.008512. Epub 2015 Feb 5.

48.

Blood pressure and hypertension in athletes: a systematic review.

Berge HM, Isern CB, Berge E.

Br J Sports Med. 2015 Jun;49(11):716-23. doi: 10.1136/bjsports-2014-093976. Epub 2015 Jan 28. Review.

PMID:
25631543
49.

Regulation and governance of multinational drug trials in stroke: barriers and possibilities.

Berge E, Ford GA, Bath PM, Stapf C, van der Worp HB, Demotes J, Broderick J, Al-Shahi Salman R, Lees KR; ESO Trials Network Committee.

Int J Stroke. 2015 Apr;10(3):425-8. doi: 10.1111/ijs.12427. Epub 2015 Jan 12.

PMID:
25580572
50.

Response to letter regarding article, "Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke".

Jusufovic M, Sandset EC, Berge E; Scandinavian Candesartan Acute Stroke Trial Study Group.

Stroke. 2015 Jan;46(1):e14. doi: 10.1161/STROKEAHA.114.007859. Epub 2014 Dec 9. No abstract available.

Supplemental Content

Support Center